FMP
Sep 29, 2024 11:00 AM - Alex Lavoie(Last modified: Sep 30, 2024 6:50 AM)
Image credit: Google Images
Milestone Scientific Inc. (NYSEAMERICAN:MLSS) operates in the medical device industry, focusing on developing and commercializing innovative injection technologies. This sector is highly competitive, with companies constantly striving to innovate and improve their financial metrics to attract investors. Return on Invested Capital (ROIC) and Weighted Average Cost of Capital (WACC) are critical indicators of a company's financial health and efficiency. ROIC measures how well a company generates returns from its invested capital, while WACC represents the average rate a company expects to pay its security holders to finance its assets.
In the comparison with its peers, Milestone Scientific Inc. shows a negative ROIC of -80.68%, which is significantly lower than its WACC of 8.60%. This results in a ROIC/WACC Ratio of -9.39, indicating that the company is not generating sufficient returns on its invested capital to cover the cost of its capital. This is a concerning sign for investors as it suggests that the company is losing value.
On the other hand, PAVmed Inc. (NASDAQ:PAVM) demonstrates an exceptionally high ROIC of 1151.73% against a WACC of only 3.70%, leading to an astounding ROIC/WACC Ratio of 311.17. This indicates that PAVmed Inc. is highly efficient in generating returns on its invested capital, far exceeding the cost of its capital. Such a high ratio is indicative of a company that is not only growing but also creating substantial value for its investors, making it a potentially attractive investment opportunity.
The other peers in the comparison, including InfuSystem Holdings, Inc. (NYSEAMERICAN:INFU), STRATA Skin Sciences, Inc. (NASDAQ:SSKN), Retractable Technologies, Inc. (NYSEAMERICAN:RVP), and OncoCyte Corporation (NYSEAMERICAN:OCX), show varying degrees of financial efficiency. However, none come close to the performance of PAVmed Inc., with most showing negative ROIC values or ROIC/WACC Ratios that indicate they are not generating returns in excess of their capital costs.
This analysis highlights the importance of examining ROIC and WACC ratios when evaluating investment opportunities in the medical device sector. While Milestone Scientific Inc. and several of its peers struggle with negative returns on invested capital, PAVmed Inc. stands out as a clear leader, suggesting it may offer the most promising investment opportunity based on these metrics.
May 14, 2024 11:41 AM - Sanzhi Kobzhan
A stock's target price, also known as its fair value, is an indication of what a share can cost based on the company’s forecasted financial statements. It is important to know a stock's fair value to find undervalued stocks with great growth potential. Let's consider how investment analysts calculat...
May 16, 2024 8:06 PM - Gordon Thompson
On Thursday, May 16, 2024, Deutsche Bank upgraded its rating on NASDAQ:ASTS to Buy, maintaining a hold position. At the time of the announcement, ASTS was trading at $4.03. This decision was accompanied by an increase in the price target for AST SpaceMobile, raised to $22 from $19, as detailed in a ...
May 24, 2024 9:30 AM - Rajnish Katharotiya
Earnings call transcripts are invaluable resources for investors, analysts, and financial enthusiasts. They provide insights into a company's performance, strategy, and future outlook, making them essential for making informed investment decisions. With Financial Modeling Prep, Earnings Call Transcr...